If you spend any time in the wellness or longevity corners of the internet, you’ve probably run into fatty15 — the supplement built around pentadecanoic acid, or C15:0. It’s being marketed as the first newly recognized essential fatty acid in nearly a century. That’s a big claim, and as a registered dietitian who believes in testing, not guessing (#TheHealthyRD), I wanted to look past the marketing and into the actual research before forming an opinion.

Here’s what I found — the real story of C15:0, what fatty15 is, and where the evidence is strong versus still early, broken down benefit by benefit.

What Is C15:0, and Why Is Everyone Talking About It?

Pentadecanoic acid (C15:0) is an odd-chain saturated fatty acid — meaning it has an odd number of carbon atoms, unlike the even-chain saturated fats (like palmitic and stearic acid) that make up most of the fat in the American diet. It’s found naturally in whole-fat dairy — milk, butter, cheese, full-fat yogurt — and in trace amounts in some fish and ruminant meats (Topvitamine, 2026).

For decades, odd-chain fatty acids were treated as biochemical background noise. That changed when veterinary epidemiologist Dr. Stephanie Venn-Watson noticed that the longest-living dolphins in a Navy research population had unusually high blood levels of C15:0. Her team’s original 2020 paper showed C15:0 actively reduced inflammation, anemia, dyslipidemia, and fibrosis in animal models — the first direct evidence that it wasn’t just a passive marker of dairy intake, but an active player in metabolic health (Venn-Watson, Lumpkin & Dennis, Scientific Reports, 2020). That observation has since produced more than 150 peer-reviewed publications and underlies fatty15, the supplement built around a patented, dairy-free form of C15:0 called FA15 (fatty15, 2026).

Heart Health: Promising Observational Data, but Causality Isn’t Settled

This is where I want to be most careful, because it’s also where the marketing tends to outrun the science.

A pooled analysis of 18 prospective cohort studies found a 12% lower risk of incident cardiovascular disease among people in the highest quintile of circulating C15:0 versus the lowest (narrative review, 2026). Other large cohorts, including CARDIA and ARIC, found that higher plasma C15:0 was associated with modestly lower systolic and diastolic blood pressure and a lower 10-year risk of incident hypertension (Frontiers in Nutrition, 2026).

But here’s the part that matters for anyone evaluating the “heart-healthy” claim: that same CARDIA/ARIC study ran Mendelian randomization analysis — a method that tests whether an association is likely to be causal — and found no evidence that C15:0 causally lowers blood pressure or cardiovascular risk. The authors concluded the collective evidence is not consistent with a causal cardiovascular benefit of C15:0 (Frontiers in Nutrition, 2026). C15:0 also wasn’t associated with incident CVD or echocardiographic heart function in either cohort.

My read: the population-level association between C15:0 and heart health is real and worth watching, but it’s not yet proof that raising your C15:0 will protect your heart. That’s a distinction worth holding onto.

Liver Health: The Strongest Human Trial Evidence So Far

If there’s one area where C15:0 has actual randomized, placebo-controlled human data behind it, it’s the liver. A 12-week, double-blind RCT gave 30 young adults with overweight or obesity either 200 mg of C15:0 daily (20 participants) or placebo (10 participants). Half of the treatment group reached a post-treatment C15:0 level above 5 μg/mL — and in that higher-responder group, researchers saw significantly greater drops in two liver enzymes, ALT (−29 U/L) and AST (−6 U/L), plus a meaningful rise in hemoglobin (+0.60 g/dL), compared to treatment-group participants who didn’t reach that threshold. No significant adverse events occurred in either arm (Robinson et al., The Journal of Nutrition, 2024). Separately, the TANGO trial paired C15:0 with an Asian-adapted Mediterranean diet for fatty liver disease and reported encouraging results.

Worth reading carefully: the strongest result here is a within-treatment-group comparison — high responders versus low responders — not a head-to-head against placebo. That’s still meaningful (it shows a dose-response relationship, which strengthens the case for a real biological effect), but it’s a step below “C15:0 beat placebo on liver enzymes,” which is how this trial sometimes gets summarized. It’s a small trial — 30 total participants — but it’s a genuine RCT with hard clinical endpoints, which puts it a step above most of what else exists in the C15:0 literature right now.

Energy, Fatigue, and Mitochondrial Function: Mechanistically Interesting, Not Yet Proven in Humans

This is the area I’d flag as the most speculative of the bunch, even though it’s often front and center in fatty15’s own marketing.

Cell-based and animal research shows that C15:0 supports mitochondrial function — the part of the cell responsible for energy production — including one study reporting a 45% reduction in damaging reactive oxygen species and improved cellular energy output at the mitochondrial level (fatty15 research timeline, 2026). A related endocannabinoid metabolite of C15:0, pentadecanoylcarnitine, has also shown anti-inflammatory, cell-based activity relevant to mood and physical health in lab studies (Venn-Watson et al., Scientific Reports, 2022).

What I don’t see yet is a published, controlled human trial measuring fatigue or energy levels as an outcome. The company’s own product page cites that 70% of customers self-report improved energy, sleep, and mood within 16 weeks — but that’s a company-reported customer survey, not a peer-reviewed clinical trial, and it comes with the placebo effect and selection bias you’d expect from any subscription-supplement testimonial data (fatty15 product page, 2026). The mitochondrial mechanism is legitimate and worth researching further — I just wouldn’t treat “boosts energy” as an established, clinically proven benefit yet.

One lab study adds an interesting, if still preliminary, data point on the mood side. Researchers ran C15:0 through the same 12-cell-system human tissue panel used to screen drug candidates and compared it directly to EPA, a leading omega-3 fatty acid. C15:0 was non-cytotoxic at every dose tested, while EPA was toxic to four of the cell systems at its highest dose, and C15:0 showed 28 additional anti-inflammatory activities beyond the ones the two fats shared. At its lowest tested doses, C15:0’s cell-based activity pattern closely resembled bupropion, a medication used to treat depression and mood disorders (Venn-Watson & Butterworth, PLOS ONE, 2022). That’s a lab-dish resemblance to a mood medication, not evidence that C15:0 treats mood disorders in people — but it’s a plausible mechanistic thread connecting the unsolicited “mood” reports mentioned later in this post to something more than anecdote.

Cognition and Brain Health: Early but Intriguing

This is the newest thread in the C15:0 research, and it’s the one I’d watch most closely over the next few years — while treating it as the earliest-stage claim on this list.

The lead comes from the same Navy dolphin population that started this whole research area. Aging dolphins develop amyloid-beta plaques and neuroinflammation strikingly similar to Alzheimer’s disease in humans, concentrated in the hippocampus, the brain’s memory center. When researchers tested C15:0 against a panel used to screen Alzheimer’s drug candidates, it acted as a dose-dependent inhibitor of two enzymes tied to cognitive decline — FAAH, with up to 89% inhibition, and MAO-B, with up to 70% inhibition — both linked to amyloid processing, neuroinflammation, and dopamine regulation (Venn-Watson et al., International Journal of Molecular Sciences, 2025). Separately, observational research has found that people with type 2 diabetes who have higher plasma C15:0 tend to score better on cognitive testing (same study, background citation).

What’s missing here is the most important piece: there is no published human trial testing C15:0 or fatty15 against memory, cognitive decline, or Alzheimer’s risk directly. This is enzyme and tissue-level evidence from an animal model, plus a correlational finding in one patient population — a legitimate and interesting starting point for further research, not a basis for a brain-health claim yet. If cognitive support is your main interest, I’d treat this as one to watch rather than one to act on.

A Word on “Cellular Fragility Syndrome”

You may also come across the term Cellular Fragility Syndrome (sometimes called C15:0 Deficiency Syndrome) in fatty15’s marketing — the idea that circulating C15:0 below roughly 0.2% of total fatty acids leaves cell membranes fragile and vulnerable to premature aging (Venn-Watson, Nutrients, 2024). It’s worth knowing that this is a term coined by the company behind fatty15, not a diagnosis recognized by major medical organizations, and it hasn’t been independently validated (Topvitamine, 2026). That doesn’t make the underlying cell-membrane research invalid — but I’d treat “syndrome” language from a supplement company with appropriate skepticism until it’s replicated by independent researchers.

Why This Matters Even More If You’re Dairy-Reactive

Here’s where my clinical experience adds something the research alone doesn’t cover. Whole-fat dairy is the primary dietary source of C15:0 — but in my time running MRT/LEAP testing with clients, I’ve seen just how large a percentage of people carry some degree of inflammatory reaction to dairy, whether it’s a full intolerance, a delayed immune reaction, or a milder sensitivity they’ve never had reason to identify. For those clients, “just eat more full-fat yogurt and butter” isn’t good advice — it’s a recommendation that can quietly work against them.

This is exactly why a supplement route to C15:0 is so relevant for a meaningful chunk of the population: it lets you raise this specific fatty acid without the dairy proteins that are actually driving inflammation for a lot of people. But that only works if you know where you stand. If you’ve never been tested and don’t actually know whether dairy is a trigger for you, that’s worth finding out — not guessing about. It’s a perfect example of why I built my whole approach around test, not guess: you can’t make a smart call about a supplement like fatty15 versus food-based C15:0 if you don’t know how your own body is responding to dairy in the first place.

Risk-Benefit Analysis

Putting all of this together, here’s how I’d weigh it for a typical client asking whether fatty15 is worth trying.

My bottom line: the risk profile is low — this isn’t a supplement I’d worry about someone trying. The benefit case is genuinely stronger than most trending longevity supplements I evaluate, thanks to actual RCT data on liver markers, but it’s not yet strong enough to call it essential or to expect dramatic results. It’s a reasonable, low-risk experiment for the right person — particularly someone who’s dairy-sensitive and testing their labs along the way — not a proven fix.

What Actual Users Are Saying (Unsolicited Reviews)

Company testimonials and customer surveys are one thing — commentary from unaffiliated, unpaid users in forums and comment sections is another, and it’s worth pulling in as a reality check on the research.

Positive experiences show up consistently around energy, mood, sleep, and skin. In the comments of a Substack post explaining the C15:0 research, one reader who had taken fatty15 for over four years described ongoing improvements in energy, mood, sleep, and blood test results, while another reader who’d been taking it since that fall reported subtler but real changes in skin, mood, sleep, and cognitive function, while noting the price felt comparable to a monthly prescription (Great Books Great Minds Substack, comments). On another Substack thread, a longtime user called it the one supplement she’s taken consistently for years (Melanie Masarin Substack, comments). A Trustpilot reviewer — self-identified as a nurse who researched the science before ordering — said the evidence behind fatty15 struck her as unusually strong, though she noted it was too early in her own use to report results (Trustpilot, 2025).

Mixed and cautionary reports exist too, and they’re worth taking seriously. In a Parkinson’s patient community, one long-term user taking fatty15 alongside high-dose thiamine (B1) therapy reported a notable drop in their B1 tolerance and new anxiety symptoms after starting the supplement, and speculated — without medical confirmation — that improved mitochondrial function from the C15:0 might have changed how their body was using the B1 (HealthUnlocked, Cure Parkinson’s community). That’s a single, unverified, self-reported account in a niche patient population on a specific concurrent protocol — not evidence of a general interaction — but it’s a useful reminder that “well-tolerated in trials” doesn’t mean risk-free for everyone, especially anyone managing a complex condition or stacking supplements.

The pattern across unsolicited reviews largely mirrors the clinical research: subtle, gradual improvements reported by long-term users, nothing dramatic or fast, and — as always with self-reported anecdotes — no way to rule out placebo effect. If you decide to try it, that’s exactly why I’d pair it with actual before-and-after labs rather than relying on how you feel alone.

Should You Take It?

My honest, clinical take: C15:0 is one of the more legitimately interesting nutrients to emerge in functional nutrition in the last few years, and it’s worth watching — especially the liver data. If you’re curious about raising your levels, you have two real options:

• Food first — if dairy agrees with you. Whole-fat dairy is the most reliable dietary source. If you already tolerate dairy well, shifting from low-fat to whole-fat versions is a reasonable, low-cost way to increase intake.
• Supplementation, like fatty15’s 100 mg capsule, if dairy isn’t part of your diet, you’re managing a dairy sensitivity, or you want a more concentrated, consistent dose in the 100–200 mg range studies have used. If you want help figuring out where something like this fits alongside the rest of your supplement stack, I keep my personal recommendations organized in my Fullscript dispensary — it’s the same place I build out protocols with my own clients.

Where I’d apply real caution is treating it as a guaranteed fix for heart health, energy, or metabolic function, or a substitute for the fundamentals — protein intake, fiber, sleep, and the other levers we already have strong evidence for. This is exactly the kind of nutrient I evaluate with clients using the same test, not guess framework I use for everything else in functional nutrition — checking where someone’s actual levels and labs stand before adding another supplement to the shelf. If you want a deeper look at how I approach building a personalized supplement and lab strategy, I break that down over at The Healthy RD and in my functional nutrition testing guides.

Frequently Asked Questions

Is fatty15 safe?

Current evidence suggests a favorable safety profile: no serious adverse events across the published human trials to date, and C15:0 has FDA “Generally Recognized As Safe” (GRAS) status. Mild, infrequent side effects are reported — occasional constipation, diarrhea, or headaches, in a small minority of users. Long-term safety data doesn’t exist yet, since every human trial so far has run 12 weeks or less.

How much C15:0 is in dairy, and what dose has been studied?

C15:0 is found naturally in whole-fat dairy — milk, butter, cheese, full-fat yogurt — and in trace amounts in some fish and ruminant meats. Human trials have studied doses in the 100–200 mg/day range.

Does fatty15 actually help with liver health?

This is the area with the strongest human trial evidence so far. In a 12-week, double-blind RCT, participants who reached a post-treatment C15:0 level above 5 μg/mL saw significantly greater drops in two liver enzymes, ALT (−29 U/L) and AST (−6 U/L), plus a meaningful rise in hemoglobin (+0.60 g/dL), compared to those who didn’t reach that threshold. That said, this was a within-treatment-group comparison, not a head-to-head against placebo, and the trial was small (30 total participants).

Is C15:0 an official essential fatty acid?

No — it hasn’t yet earned official “essential fatty acid” status. Only omega-3 and omega-6 fatty acids currently carry that designation. C15:0 is a genuinely interesting candidate, but the human trial base is still small, short-term, and largely funded by the company that also sells the supplement.

Does fatty15 help with energy, mood, or cognition?

The mitochondrial and mood-related mechanisms are biologically plausible and supported by cell-based and animal research, but there is no published, controlled human trial measuring fatigue, mood, or cognitive outcomes directly. The company’s own claim that 70% of customers report improved energy, sleep, and mood is based on a customer survey, not a peer-reviewed clinical trial. On cognition specifically, the evidence is limited to enzyme inhibition studies in dolphin brain tissue and one observational link in people with type 2 diabetes — no human trial has tested it against memory or cognitive decline directly.

The Bottom Line

C15:0 has a genuinely compelling research story behind it — dolphins, population data, plausible mechanisms, and a small but real RCT on liver enzymes. The heart-health claim is backed by observational data but not yet by causal evidence, and the energy/fatigue claim is mechanistically plausible but still short on human trial data. It hasn’t yet earned official “essential fatty acid” status. That makes it a reasonable thing to experiment with under the right conditions — not a reason to overhaul your supplement routine overnight.

For more on how I evaluate emerging supplements and build individualized nutrition protocols, visit thehealthyrd.com.

Sources

1. Venn-Watson & Schork, “Pentadecanoic Acid Shares Clinically Relevant Cell-Based Activities with Leading Longevity-Enhancing Compounds”, Nutrients (2023)
2. Robinson et al., “Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial”, The Journal of Nutrition (2024)
3. Chooi et al., “Effect of an Asian-adapted Mediterranean Diet and Pentadecanoic Acid on Fatty Liver Disease: The TANGO Randomized Controlled Trial,” American Journal of Clinical Nutrition (2024)
4. “Plasma Pentadecanoic Acid Is Modestly Related to Cardiovascular Health in CARDIA and ARIC Cohorts”, Frontiers in Nutrition (2026)
5. “Pentadecanoic Acid (C15:0) and Cardiovascular Disease: A Narrative Review” (2026)
6. Venn-Watson et al., “Pentadecanoylcarnitine Is a Newly Discovered Endocannabinoid with Pleiotropic Activities Relevant to Supporting Physical and Mental Health”, Scientific Reports (2022)
7. Venn-Watson, “The Cellular Stability Hypothesis: Evidence of Ferroptosis and Accelerated Aging-Associated Diseases as Newly Identified Nutritional Pentadecanoic Acid (C15:0) Deficiency Syndrome” (2024)
8. “C15 Fatty Acid Supplements: A Complete Guide to Benefits, Science, and Safety”, Topvitamine (2026)
9. “Pentadecanoic Acid Research: A Timeline of Key Studies (2015–2026)”, fatty15
10. fatty15 product page, “C15:0 Fatty Acid Supplement (Pentadecanoic Acid)”
11. Venn-Watson, Lumpkin & Dennis, “Efficacy of Dietary Odd-Chain Saturated Fatty Acid Pentadecanoic Acid Parallels Broad Associated Health Benefits in Humans: Could It Be Essential?”, Scientific Reports (2020)
12. Venn-Watson & Butterworth, “Broader and Safer Clinically-Relevant Activities of Pentadecanoic Acid Compared to Omega-3: Evaluation of an Emerging Essential Fatty Acid Across Twelve Primary Human Cell-Based Disease Systems”, PLOS ONE (2022)
13. Jenkins et al., “Odd Chain Fatty Acids: New Insights of the Relationship Between the Gut Microbiota, Dietary Intake, Biosynthesis and Glucose Intolerance”, Scientific Reports (2017)
14. Venn-Watson et al., “Aging-Associated Amyloid-β Plaques and Neuroinflammation in Bottlenose Dolphins and Novel Cognitive Health-Supporting Roles of Pentadecanoic Acid (C15:0)”, International Journal of Molecular Sciences (2025)